New York Health Policy Monitor (April 14, 2026)
Legislature advances FQHC alternative payment models, authorizes hospice care in MLTCs, and mandates new community advisory boards for all hospitals.
Recent legislative activity introduces several measures poised to impact Medicaid managed care and broader insurance coverage frameworks across New York. Lawmakers have introduced a measure directing the Department of Health to establish an alternative payment methodology for federally qualified health centers providing fertility care. Additionally, new proposals would permit individuals receiving hospice services to enroll in managed long-term care plans, addressing current barriers to coordinated service delivery. Another bill aims to provide state premium assistance for residents losing insurance due to federal policy changes.
Hospital operations and compliance mandates are also a significant focus of the current legislative session. A new proposal would require every general hospital to establish a community advisory board to advise on institutional plans and programs. Furthermore, legislation has been introduced to establish procedures for the social admission of minors who are medically cleared for discharge but abandoned at emergency departments. Other bills seek to expand insurance coverage mandates for non-pharmacological chronic pain treatments and grant peace officer status to security personnel at specific hospital campuses.
Workforce regulation and programmatic oversight feature prominently in the latest bill introductions. The legislature is considering the Oversight of Health Programs Act, which would allow specific legislative members to request records from state vendors administering publicly subsidized health programs. Additional measures would mandate criminal background checks for all certified emergency medical services personnel and reconfigure the composition of professional medical conduct committees. Lawmakers have also introduced legislation to automatically align state schedules of controlled substances with federal redesignations, ensuring immediate access to approved therapies.
Prepared by Isaac Michaels, DrPH · April 14, 2026